Skip to main content

Market Overview

Biohaven Secures $100M Milestone Funding After Enrolling First Patient In Migraine Study With Oral Zavegepant

  • Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) has enrolled the first patient in a Phase 2/3 trial evaluating oral zavegepant for migraine's preventive treatment, triggering a milestone funding payment of $100 million.
  • In August last year, Biohaven entered into a funding agreement with Royalty Pharma to secure up to $250 million to advance the development of zavegepant in migraine and other CGRP-mediated diseases. 
  • The randomized, double-blind, placebo-controlled trial will enroll approximately 2,900 people with migraines and evaluate the efficacy and safety of 100 mg and 200 mg doses of oral zavegepant.
  • The Zavegepant program encompasses intranasal and oral formulations for migraine and non-migraine indications.
  • Intranasal zavegepant previously demonstrated superior efficacy to placebo in a Phase 2/3 study for migraine's acute treatment.
  • The drug is also being studied in an ongoing trial in COVID-19 infected hospitalized patients requiring supplemental oxygen.
  • Price Action: BHVN shares are trading 4.58% lower at $63.5 on the last check Monday.

Related Articles (BHVN)

View Comments and Join the Discussion!

Posted-In: MigrainesBiotech News Health Care Financing FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at